Fat Metabolism Peptides
Affects fat storage and burning
Fat metabolism peptides influence how the body stores, mobilizes, and burns fat. AOD-9604 is a fragment of growth hormone (amino acids 176-191) that specifically targets fat cells without the growth-promoting effects of full GH. It stimulates lipolysis (fat breakdown) and inhibits lipogenesis (new fat storage). GLP-1 agonists reduce fat mass primarily through caloric deficit created by appetite suppression, but they also appear to have direct effects on fat tissue and visceral fat reduction.
Growth hormone secretagogues (CJC-1295, ipamorelin, GHRP-2) promote fat metabolism indirectly by elevating GH, which shifts the body's fuel preference from glucose to fatty acids, particularly during fasting and sleep. Tesamorelin is FDA-approved specifically for reducing visceral fat accumulation. MOTS-c activates AMPK, which promotes fatty acid oxidation in muscle tissue.
This page collects every peptide on PeptideWiki tagged for fat metabolism. Browse individual profiles for mechanisms, dosing, and safety data.
Peptides (10)
CJC-1295 with DAC
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting growth hormone-releasing compound that binds to a blood protein called albumin, extending its active life to several days. This provides sustained growth hormone elevation compared to the shorter-acting Mod GRF 1-29.
CJC-1295 (Modified GRF 1-29)
CJC-1295 without DAC (also called Modified GRF 1-29) is a synthetic growth hormone-releasing compound with a short active window of about 30 minutes. It is being studied for its effects on growth hormone release and body composition.
MK-677 (Ibutamoren)
MK-677 (Ibutamoren) is an oral (non-injectable) compound that triggers growth hormone release by mimicking the hunger hormone ghrelin. Research focuses on increasing growth hormone and IGF-1 levels, improving sleep quality, body composition, and bone density.
Tesamorelin
Tesamorelin is a synthetic growth hormone-releasing compound used for reducing deep abdominal fat in patients with lipodystrophy (abnormal fat distribution). It is FDA-approved and marketed as Egrifta, specifically targeting visceral fat accumulation.
Sermorelin
Sermorelin is a synthetic 29-amino-acid growth hormone-releasing compound. It was FDA-approved for pediatric growth hormone deficiency and is widely used off-label for anti-aging and body composition improvement.
Ipamorelin
Ipamorelin is a selective compound that triggers growth hormone release, originally developed by Novo Nordisk. It stimulates growth hormone without significantly affecting cortisol or prolactin levels. It has been studied in clinical trials for postoperative recovery.
5-Amino-1MQ
5-Amino-1MQ is a small molecule that blocks an enzyme linked to fat storage and metabolic problems. Research focuses on fat cell metabolism, weight loss, and reversing diet-related obesity in animal studies.
HGH Fragment 176-191
HGH Fragment 176-191 is a stabilized piece of human growth hormone (amino acids 176-191) and the parent compound of AOD-9604. Research focuses on fat breakdown without the growth-promoting or blood sugar effects of full growth hormone.
AOD-9604
AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191). Originally developed as an anti-obesity compound, it shows preclinical evidence for promoting fat metabolism without affecting blood sugar or growth.
GHRP-2
GHRP-2 (Growth Hormone Releasing Peptide-2) is a synthetic six-amino-acid peptide that triggers growth hormone release. It is considered more potent than GHRP-6 with less appetite stimulation.